Peanut Allergy Treatment and Me
April 3rd, 2007The Whitehouse Station-based company said it expects to post first-quarter earnings per share of 58 cents to 64 cents, or 63 cents to 67 cents excluding restructuring charges. Analysts surveyed by Thomson Financial on average were expecting only 60 cents, excluding charges. Merck, the maker of osteoporosis treatment Fosamax Peanut Allergy Treatment and Singulair for asthma and allergies, also said it expects earnings per share of $2.55 to $2.65 for the full year, excluding restructuring charges